Compare OZ & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | AARD |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 281.1M |
| IPO Year | 2020 | N/A |
| Metric | OZ | AARD |
|---|---|---|
| Price | $50.01 | $4.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | 9.6K | ★ 203.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.68 | N/A |
| 52 Week Low | $48.50 | $4.88 |
| 52 Week High | $82.89 | $17.94 |
| Indicator | OZ | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 16.48 |
| Support Level | $49.79 | N/A |
| Resistance Level | $64.85 | $15.88 |
| Average True Range (ATR) | 0.68 | 0.58 |
| MACD | 0.28 | -0.69 |
| Stochastic Oscillator | 57.28 | 1.94 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.